AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd's Syndicate 1902, for its Phase III clinical trial ...
(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announced today the results from a phase 3 ...
PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM, SUSPENDING SOME NON-PRIORITY CLINICAL TRIALS TO FOCUS ON TWO CLINICAL ...
AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the shelf-life of its veterinary medicine MASIVET® from 36 months to ...
i) Approval by several European countries to initiate the confirmatory Phase 3 trial AB Science announced in July 2025 that the confirmatory Phase 3 trial with masitinib in amyotrophic lateral ...
Ab Science ((ABSCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
(RTTNews) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that it has received Chinese patent protecting Masitinib in the treatment of Covid-19 until April 2041. In Paris, AB ...
AB SCIENCE REPORTS COMPLETION OF THE STEP 3 OF PHASE 1, EVALUATING THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA THE COMBINATION OF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results